bFGF peptide combined with the pVAX-8CpG plasmid as adjuvant is a novel             anticancer vaccine inducing effective immune responses against Lewis lung carcinoma.
Due to the poor immunogenicity of subunit protein antigens, there is a need             to use adjuvants in order to generate effective immune responses. Basic fibroblast             growth factor (bFGF) is one of the best characterized pro-angiogenic cytokine             and is a candidate target for anticancer therapy. We used truncated bFGF (tbFGF)             combined with engineered pVAX-nCpG as novel adjuvant to immunize mice in order             to inhibit tumor angiogenesis and suppress tumor growth. In our study, the results             demonstrated that the mice immunized with tbFGF-alum-pVAX-8CpG produced a better             tumor-suppression effect compared with the other groups, apart from the group             treated with tbFGF-alum-CpG. In addition, the function of immune modulation of             pVAX-8CpG was similar to CpG ODNs. The vaccine composed of tbFGF, alum and pVAX-8CpG             effectively inhibited tumor angiogenesis and induced strong antitumor immune responses.             The antitumor activity induced by the vaccine tbFGF-alum-pVAX-8CpG was not only             associated with the antigen-specific antibody, but also with the killing activity             of cytotoxic cells. This indicates that alum-pVAX-8CpG may be an innovative adjuvant             for cancer vaccines.
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, PR China.
Meng
M
Li
Hua Shan
HS
Shi
Hai Long
HL
Zhang
Zi Chao
ZC
Luo
Yang
Y
Wan
Lian
L
Lu
Shun-Tao
ST
Luo
Li
L
Yang
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000534:Alum Compounds / Q000627:therapeutic use; D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology / Q000378:metabolism; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D018827:Carcinoma, Lewis Lung / Q000276:immunology / Q000628:therapy*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009389:Neovascularization, Pathologic; D010957:Plasmids / Q000378:metabolism / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D057134:Antibodies, Neutralizing; D019496:Cancer Vaccines; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2